Scholarlink

<p>The updated S3&#xa0;guideline for supportive care (version&#xa0;2.0, as of April 2025) provides an evidence-based, interdisciplinary framework for the supportive management of oncology patients. Supportive care encompasses measures aimed at preventing and managing therapy-induced side effects, with the goal of maintaining quality of life, avoiding therapy discontinuation, and ensuring holistic patient care. The new version expands the previous ten topic areas with four central focuses: management of side effects from immunotherapies, cardiovascular complications, central neurotoxicity, and radiation-induced side effects in the genitourinary tract. The guideline offers concrete recommendations for monitoring, prevention, and management of side effects associated with modern therapies, emphasizing the importance of patient-centered and interdisciplinary care. For urologists, the explicit discussion of radiation-induced side effects in the genitourinary tract is particularly relevant, including incontinence, bladder emptying disorders, and sexual dysfunction. The guideline supports structured long-term follow-up, enhances interdisciplinary collaboration, and enables evidence-based planning and management of side effects. Despite comprehensive evidence, the effectiveness of the guideline critically depends on consistent implementation, sufficient resources, and individualized adaptation to patients. The S3&#xa0;guideline 2025 thus provides a&#xa0;foundation for optimized supportive care in urologic oncology and promotes sustainable improvement of function and quality of life for patients.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Neue Leitlinie „Supportivtherapie“ – was ist für den Urologen relevant?

  • 期刊论文

  • 发表日期：

    2026年3月30日

查看全文
  • Désirée Louise Dräger,
  • Chris Protzel

摘要

The updated S3 guideline for supportive care (version 2.0, as of April 2025) provides an evidence-based, interdisciplinary framework for the supportive management of oncology patients. Supportive care encompasses measures aimed at preventing and managing therapy-induced side effects, with the goal of maintaining quality of life, avoiding therapy discontinuation, and ensuring holistic patient care. The new version expands the previous ten topic areas with four central focuses: management of side effects from immunotherapies, cardiovascular complications, central neurotoxicity, and radiation-induced side effects in the genitourinary tract. The guideline offers concrete recommendations for monitoring, prevention, and management of side effects associated with modern therapies, emphasizing the importance of patient-centered and interdisciplinary care. For urologists, the explicit discussion of radiation-induced side effects in the genitourinary tract is particularly relevant, including incontinence, bladder emptying disorders, and sexual dysfunction. The guideline supports structured long-term follow-up, enhances interdisciplinary collaboration, and enables evidence-based planning and management of side effects. Despite comprehensive evidence, the effectiveness of the guideline critically depends on consistent implementation, sufficient resources, and individualized adaptation to patients. The S3 guideline 2025 thus provides a foundation for optimized supportive care in urologic oncology and promotes sustainable improvement of function and quality of life for patients.